Asthma and COPD Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

The Asthma and COPD Drugs Market is segmented by Drug Class, Indication, and Geography.

Asthma and COPD Drugs Market Snapshot

Study Period:


Base Year:


Fastest Growing Market:

Asia Pacific

Largest Market:

North America


4.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Asthma and COPD drugs market is expected to witness a CAGR of 4.2% during the forecast period. Certain factors that are driving the market growth include an increase in incidence and prevalence of asthma and COPD, technological advancements, and growing geriatric population.

  • The global population is aging rapidly, owing to reduced birth rates and increasing life expectancy. According to the US Census Bureau’s Statistics, as of 2017, the total number of people aged between 65 years and older, exceeded 50 million. According to the United Nations, during the period of 2015-2030, the number of older persons aged 60 years or over, worldwide, is projected to grow by 56% (from 901 million to more than 1.4 billion).
  • Moreover, economic and social commission for Asia and the Pacific (ESCAP), reports that the geriatric population in Asia-Pacific was around 548 million in 2019, accounting for more than half of the world’s total elderly population. It is estimated that, by 2050, Asia-Pacific may account for almost two-thirds of the world’s geriatric population. Hence, owing to the fact that asthma is a widely prevalent disease found in people over age 65, the growing geriatric population is expected to drive the market growth over the forecast period.
  • In addition, technological advancements are anticipated to provide the market lucrative opportunities. Limitations of traditional treatments, such as late onset of action and low efficacy, are projected to encourage the development of novel targeted drug, thereby boosting growth during the future period.

Scope of the Report

Asthma is a chronic respiratory disease, which blocks the airways of the lung because of mucus production, inflammation, and tightening of muscles. Similarly, chronic obstructive pulmonary disease (COPD) is caused by the blockage in the airways, further resulting in difficulty in breathing. Asthma and COPD drugs are drugs that are used to treat these aforementioned respiratory diseases.

By Drug Class
Short Acting Beta-2 Agonists
Long Acting Beta-2 Agonists
Anti-cholinergic Agents
Anti-inflammatory Drugs
Oral and Inhaled Corticosteroids
Phosphodiesterase Type-4 Inhibitors
Other Anti-inflammatory Drugs
Monoclonal Antibodies
Combination Drugs
By Indication
Chronic Obstructive Pulmonary Disease
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East & Africa
South Africa
Rest of Middle East & Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Asthma is Expected to Hold the Largest Market Share in the Indication Type

According to the American Academy of Allergy Asthma and Immunology (AAAI), in 2016, approximately 8.3% of children in the United States were found to have asthma. Boys were to some extent more likely to have asthma than girls at a rate of 9.2% and 7.4%, respectively. Asthma incidence among children increased from 8.7% in 2001 to 9.4% in 2010 and then declined to 8.3% in 2016. Although not all changes were statistically noteworthy, a similar outline was observed among the sub-demographic groups, except the Mexican/Mexican-American children, among whom asthma prevalence increased from 5.1% in 2001 to 6.5% in 2016. The substantial increase in prevalence and incidence of asthma has led to an increase in the patient population, which has, in turn, increased the demand for these drugs.

Moreover, the rise in the number of initiatives undertaken by government and nongovernment organizations is increasing the overall revenue. For instance, CDC’s National Asthma Control Program (NACP) provides funds for educating asthma affected patients. Such initiatives are likely to increase awareness about asthma, which will increase the adoption of drugs in the treatment of asthma, leading to verticle growth.

To understand key trends, Download Sample Report

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate asthma and COPD drugs market during the forecast period. This growth can be attributed to the rising incidence of diseases such as COPD and asthma. According to the Annals of the American Thoracic Society, asthma costs the U.S. economy more than USD 80 billion annually in medical expenses, missed work and school days and deaths. The rise in the number of patients affected by these diseases, increases the demand for these drugs for the treatment of target disease, thereby boosting growth of this region.

In addition, the local presence of key pharmaceutical players, advanced healthcare infrastructure, aging population, high disposable income, and lifestyle changes are factors contributing to the overall growth of the North America asthma and COPD drugs market.

To understand geography trends, Download Sample Report.

Competitive Landscape

The industry is competitive in nature with key players involved in mergers & acquisitions, new product development, collaborations & partnerships, and expansion strategies to augment market penetration. Few major players. Companies, like Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Grifols, Novartis AG, Pfizer, Roche Holding AG, and Teva Pharmaceutical, among others, hold the substantial market share in the asthma and COPD drugs market.

For instance, in May 2017, Koninklijke Philips N.V. entered into a definitive agreement to acquire Respiratory Technologies, Inc. (RespirTech) with an aim to expand its respiratory care product portfolio.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Incidence and Prevalence of Asthma and COPD

      2. 4.2.2 Technological Advancements

      3. 4.2.3 Growing Geriatric Population

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Government Regulations for the Product Approval

      2. 4.3.2 Side Effects Associated with Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Class

      1. 5.1.1 Bronchodilators

        1. Short Acting Beta-2 Agonists

        2. Long Acting Beta-2 Agonists

        3. Anti-cholinergic Agents

      2. 5.1.2 Anti-inflammatory Drugs

        1. Oral and Inhaled Corticosteroids

        2. Anti-leukotrienes

        3. Phosphodiesterase Type-4 Inhibitors

        4. Other Anti-inflammatory Drugs

      3. 5.1.3 Monoclonal Antibodies

      4. 5.1.4 Combination Drugs

    2. 5.2 By Indication

      1. 5.2.1 Asthma

      2. 5.2.2 Chronic Obstructive Pulmonary Disease

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East & Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca

      2. 6.1.2 Boehringer Ingelheim

      3. 6.1.3 GlaxoSmithKline

      4. 6.1.4 Grifols

      5. 6.1.5 Merck & Co.

      6. 6.1.6 Pfizer

      7. 6.1.7 Roche Holding AG

      8. 6.1.8 Sumitomo Dainippon Pharma

      9. 6.1.9 Teva Pharmaceutical

  7. *List Not Exhaustive

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports